MSB 2.26% 90.5¢ mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-236

  1. 5,487 Posts.
    lightbulb Created with Sketch. 8940
    another company I hold, was required to resubmit an NDA because their instruction manual wasn’t up to scratch. That is the only thing they had left to tick off… FDA forced them to wait several months just for that. so this new data was always going to need another resubmission.
    Last edited by stockrock: 26/03/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.